IMAGE trial results to be presented at International Society for Heart & Lung Transplantation meeting

XDx, Inc., a molecular diagnostics company focused on noninvasive tests for the monitoring of immune-mediated conditions, today announced that results from its Invasive Monitoring Attenuation through Gene Expression (IMAGE) trial will be presented by Dr. Michael X. Pham, Stanford University Medical Center, during a plenary session at the International Society for Heart & Lung Transplantation 30th Anniversary Meeting & Scientific Sessions in Chicago this month.

IMAGE is a multicenter, randomized clinical trial of 602 heart transplant patients comparing XDx's AlloMap® Molecular Expression Testing, a noninvasive rejection surveillance method utilizing gene expression profiling testing, to routine endomyocardial biopsy surveillance to monitor acute cellular rejection in cardiac transplant recipients. This comparative effectiveness research study was designed to demonstrate the non-inferiority of clinical outcomes of heart transplant recipients managed with the AlloMap test compared with conventional endomyocardial biopsy.

Following the plenary session, XDx is sponsoring a satellite symposium entitled: "The Future of Rejection Surveillance after Cardiac Transplantation" at 12:30 p.m. CDT in which heart transplant cardiologists will further discuss implications of the IMAGE findings. The symposium will take place in the Hilton Chicago, International Ballroom.  

SOURCE XDx, Inc.